Sanjay Mukhopadhyay, MD
- Call 216.444.5893
Insurance
Is Cleveland Clinic Part of Your Insurance?
Review a list of accepted insurance plans for our Northeast Ohio locations or learn more about purchasing a contracted managed care plan.
View All PlansAbout Sanjay Mukhopadhyay, MD
Dr. Mukhopadhyay is Director of Pulmonary Pathology at the Cleveland Clinic, Associate Editor (Pulmonary) for the American Journal of Clinical Pathology and Associate Editor (Social Media) for Modern Pathology. He attended medical school in India and completed pathology residency training at the All India Institute of Medical Sciences followed by a second pathology residency at SUNY Upstate Medical University (Syracuse, NY). After a pulmonary pathology fellowship at the Mayo Clinic (Rochester, MN), he was recruited back to Syracuse and stayed on as faculty for next 6 years, rising to the rank of tenured Associate Professor in 2011. In 2013, he joined the department of pathology at the Cleveland Clinic. His interests include granulomatous lung diseases (including infections), interstitial lung disease, smoking-related lung disease, and lung cancer. The pulmonary pathology service at Cleveland Clinic signs out 5000 cases a year and supports a large group of ILD pulmonologists and several thoracic surgeons. The lung transplant service is one of the busiest in the world.
Dr. Mukhopadhyay has authored more than 120 publications in indexed, peer-reviewed journals, including 48 first-authored papers. He is the author of a textbook on non-neoplastic lung pathology published by Cambridge University Press in 2016 and a textbook of thoracic pathology to be published by Innovative Science Press in 2022. His studies have been published in the American Journal of Surgical Pathology, American Journal of Clinical Pathology, Modern Pathology, Human Pathology, Archives of Pathology and Laboratory Medicine and Chest. In 2011, he was invited to join the faculty of the prestigious USCAP Long Course in Pulmonary Pathology. He has received several teaching awards, served on the abstract review committees of the USCAP and CAP for several years, moderated platform sessions at USCAP, and taught 3 USCAP Short Courses. Since 2016, he has pioneered the use of online platforms for teaching lung pathology globally, for which The Pathologist magazine named him to its “Power List” for 4 years in a row (2018-2021). In 2018, Dr. Mukhopadhyay first-authored a landmark study that led to FDA approval for whole slide imaging for primary diagnosis in surgical pathology in the United States. This was followed by two highly cited studies of the effects of vaping on the lung and autopsy findings in COVID-19 that generated intense interest in the national news media and online. In 2020, Dr. Mukhopadhyay was featured in a New York Times video on COVID-19 and ARDS that has been viewed more than 2 million times.
Education & Professional Highlights
Appointed
2013
Education & Fellowships
Fellowship - Mayo Clinic
Pulmonary Pathology
Rochester,
MN United States
2007
Residency - State University of New York Upstate Medical Center
Anatomic and Clinical Pathology
Syracuse,
NY United States
2006
Residency - All India Institute of Medical Sciences
Pathology
New Delhi,
India
2002
Internship - Englewood Hospital
Englewood,
NJ
1998
Medical Education - Maulana Azad Medical College, University of Delhi
New Delhi,
India
1994
Professional Highlights
- Author of lung pathology textbook: Mukhopadhyay S. Non-neoplastic Pulmonary Pathology: An Algorithmic Approach to Histologic Findings in the Lung. Cambridge, UK: Cambridge University Press; May 2016.
- Invited Faculty Speaker, USCAP Long Course in Pulmonary Pathology: "Practical Solutions to Common Problems in Pulmonary Pathology", Anna-Luise Katzenstein and Jeffrey L. Myers, Course Directors, United States and Canadian Academy of Pathology (USCAP) 2011 Annual Meeting, San Antonio, Texas, 2011
- Faculty Speaker, USCAP Short Course: "Pulmonary Infections: Morphologic and Molecular Tips for the Surgical Pathologist", with Carol Farver, MD and Gary Procop, MD. United States and Canadian Academy of Pathology (USCAP) Annual Meeting; 2015-2017
- Section Editor, Pulmonary Pathology, for the Editorial Board of Archives of Pathology and Laboratory Medicine, (2010- present)
- Member, Abstract Review Committee (Pulmonary), United States and Canadian Academy of Pathology (USCAP) Annual Meeting (2009-2011, 2014-2017)
- Member, Abstract Review Committee (Pulmonary), College of American Pathologists (CAP) Annual Meeting (2010-present)
- Moderator, Pulmonary Pathology Proffered Papers Platform Presentation Session, United States and Canadian Academy of Pathology (USCAP) Annual Meeting (2008, 2010-2013)
- Invited Speaker, Pulmonary Specialty Conference, United States and Canadian Academy of Pathology (USCAP) Annual Meeting 2009
- Pathology Reviewer, New York State Thoracic Society Annual Scientific Assembly (2009-2013)
Certifications
- Pathology - Anatomic & Clinical Pathology
Awards & Honors
- Achievement Award for Excellence in Pathology 201 Teaching, State University of New York Upstate Medical University, Syracuse, NY, 2008-2009, 2010-2011, 2012-2013
- Certificate of Appreciation, Best Teacher in Pathology Residency Program, 2008-2009
- Honorary Mention, awarded by the Pulmonary Pathology Society, for poster entitled "Occult aspiration of gastric contents in biopsy/resection specimens: an often unrecognized cause of lung infiltrates and nodules" presented at: United States and Canadian Academy of Pathology (USCAP) Annual Meeting, Atlanta, GA, 2006
- Pulmonary Pathology Society Travel Award, awarded at United States and Canadian Academy of Pathology (USCAP) Annual Meeting, Atlanta, GA, 2006
Memberships
- United States and Canadian Academy of Pathology
- Pulmonary Pathology Society
- American Society for Clinical Pathology
- College of American Pathologists
Research & Publications
See publications for Sanjay Mukhopadhyay, MD.
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 9/18/2024, Dr. Mukhopadhyay has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.
* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.
